Search hospitals

>

Quebec

>

MONTREAL

McGill University Health Centre

Claim this profile

MONTREAL, Quebec H4A 3J1

Global Leader in Lung Cancer

Global Leader in Cancer

Conducts research for Breast Cancer

Conducts research for Pancreatic Cancer

Conducts research for Ovarian Cancer

496 reported clinical trials

55 medical researchers

Photo of McGill University Health Centre in MONTREALPhoto of McGill University Health Centre in MONTREALPhoto of McGill University Health Centre in MONTREAL

Summary

McGill University Health Centre is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer and other specialties. McGill University Health Centre is involved with conducting 496 clinical trials across 869 conditions. There are 55 research doctors associated with this hospital, such as Lucy Gilbert, MD, Atul Verma, MD, Talat Bessissow, MD PhD, and Vidal Essebag, MD.

Area of expertise

1

Lung Cancer

Global Leader

McGill University Health Centre has run 62 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
PD-L1 positive
2

Cancer

Global Leader

McGill University Health Centre has run 46 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at McGill University Health Centre

Lung Cancer

Ovarian Cancer

Breast Cancer

Non-Small Cell Lung Cancer

Multiple Myeloma

Diabetes

Cancer

Prostate Cancer

Melanoma

Endometrial Cancer

Image of trial facility.

Dato-DXd + Pembrolizumab

for Advanced Lung Cancer

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.

Recruiting

2 awards

Phase 3

13 criteria

Image of trial facility.

Pembrolizumab + Sacituzumab Tirumotecan

for Lung Cancer

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Recruiting

2 awards

Phase 3

Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Lung Cancer

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.

Recruiting

2 awards

Phase 3

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at McGill University Health Centre?

Where is McGill University Health Centre located?

Who should I call to ask about financial aid or insurance network?

What insurance does McGill University Health Centre accept?

What awards or recognition has McGill University Health Centre received?